The dawn has come for new therapeutics to treat atherosclerosis: Targeting neuroimmune cardiovascular interfaces in artery brain circuits
Clin Transl Med
.
2022 Sep;12(9):e1040.
doi: 10.1002/ctm2.1040.
Authors
Sarajo Kumar Mohanta
1
2
3
,
Christian Weber
1
2
3
4
,
Changjun Yin
5
,
Andreas J R Habenicht
1
2
Affiliations
1
Institute of Cardiovascular Prevention, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
2
DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
3
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
4
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands.
5
Institute of Precision Medicine, The First Affiliated Hospital of Sun-Yat-sen University, Guangzhou, Guangdong, China.
PMID:
36052959
PMCID:
PMC9437971
DOI:
10.1002/ctm2.1040
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Arteries
Atherosclerosis* / drug therapy
Brain
Central Nervous System
Humans
Neuroimmunomodulation*